Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Vericel Corproation (VCEL)

Vericel Corproation (VCEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vericel Corproation 64 SIDNEY STREET CAMBRIDGE MA 02139 USA

P: 617-588-5555 F: 617-588-5554

Description:

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States.

Key Statistics

Overview:

Market Capitalization, $K 1,317,994
Enterprise Value, $K 1,214,594
Shares Outstanding, K 47,223
Annual Sales, $ 156,180 K
Annual Net Income, $ -7,470 K
Last Quarter Sales, $ 38,550 K
Last Quarter Net Income, $ -6,580 K
60-Month Beta 1.83
% of Insider Shareholders 5.20%
Float, K 44,767
% Float 94.80%
Short Volume Ratio 0.43

Growth:

1-Year Return -15.53%
3-Year Return 69.82%
5-Year Return 266.45%
5-Year Revenue Growth 187.20%
5-Year Earnings Growth 78.08%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.14 on 11/09/22
Next Earnings Date 02/23/23
Earnings Per Share ttm -0.39
EPS Growth vs. Prev Qtr 26.32%
EPS Growth vs. Prev Year -27.27%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 10/16/13

VCEL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -10.41%
Return-on-Assets % -7.41%
Profit Margin % -4.78
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 8.22
Price/Cash Flow N/A
Price/Book 7.60
Book Value/Share 3.77
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar